Table 1 Patients’ characteristics (n = 5,562)
From: Hepatitis C treatment initiation in HIV-HCV coinfected patients
Characteristic | Â |
|---|---|
Male, n (%) | 3976 (71.5Â %) |
Age (year), median (IQR) | 39 (35–43) |
HIV risk factor, n (%) | Â |
 Intravenous drug use | 3330 (59.9 %) |
 Hemophilia, transfusion, nosocomial | 310 (5.6 %) |
 Heterosexual contact | 990 (17.8 %) |
 Men having sex with men | 731 (13.1 %) |
 Other, unknown | 201 (3.6 %) |
Known duration of HIV infection (year), median (IQR) | 11 (5–14) |
CDC stage, n (%) | Â |
 Stage A | 2731 (49.1 %) |
 Stage B | 1204 (21.6 %) |
 Stage C | 1626 (29.2 %) |
Under cART at entry, n (%) | 3554 (63.9Â %) |
Under cART during follow up, n (%) | 1648 (29.6Â %) |
cART naive, n (%) | 360 (6.5Â %) |
Deceased | 748 (13.4Â %) |
Known duration of HCV infection (year), median (IQR) | 2 (0–7) |
HCV risk factor, n (%) | Â |
 Intravenous drug use | 3588 (64.5 %) |
 Hemophilia, transfusion, nosocomial | 339 (6.1 %) |
 Sexual | 580 (10.4 %) |
 Other, unknown | 1055 (19.0 %) |
HCV genotype information available | Â |
 All cohort | 3137 (56.4 %) |
 Patient not spontaneously cured | 3086 (59.4 %) |
HCV genotype | Â |
 Genotype 1 | 1676 (53.4 %) |
 Genotype 2 | 99 (3.2 %) |
 Genotype 3 | 763 (24.3 %) |
 Genotype 4 | 584 (18.6 %) |
 Genotype 5 | 4 (0.1 %) |
 Genotype 6 | 4 (0.1 %) |
Fibrosis evaluation, n (%) | 2869 (51.6Â %) |